Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab

(RTTNews) - Sandoz, a Novartis (NVS) division engaged in generic pharmaceuticals and biosimilars, said Thursday that the European Medicines Agency has accepted the marketing authorization applications for proposed biosimilar denosumab for regulatory review.

The two applications include all indications covered by the reference medicines Prolia (denosumab) and Xgeva(denosumab), respectively, for treating a variety of conditions, including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that have spread to the bone, and giant cell tumor of the bone.

For More Such Health News, visit rttnews.com